Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCLife®-LDD hUC-MSCs Injection Therapy for Patients With Lumbar Intervertebral Disc Degeneration
NCT06589271Phase 1Suspended
- Sponsor
- Sclnow Biotechnology Co., Ltd.
- Start
- Dec 2026
- Primary completion
- Jun 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of human umbilical cord mesenchymal stem cells in Lumbar degenerative disc disease (DDD) (2 arms), sponsored by Sclnow Biotechnology Co., Ltd. Primary endpoint: Change of lumbar disc MRI (T2WI) signal values at 12 months. Planned start Dec 2026; status: suspended.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
Lumbar degenerative disc disease (DDD)
Beyond the preview
Go deeper on NCT06589271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06589271.